Further studies are needed to provide new insights on the immunological mechanisms involved in the development of certain forms of ovarian cancer, which will be crucial for the development of new immunotherapeutic strategies (e.g., simultaneous blockage of different immune checkpoints, including hormone receptors, or infusion of antitumor lymphocytes previously engineered with CARs). The gene discussed is NR4A1; the disease is ovarian cancer.